Analytical Data
-
Gene name
SFXN3
- Application
-
Alternative Names
SFX3
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BWM7
-
Expression Region
Met1~Gln145
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SFXN3, or sideroflexin 3, is a mitochondrial protein implicated in iron homeostasis and cellular metabolism. Recent studies have highlighted its potential role in various biological processes, including oxidative stress response and neuroprotection. Research has shown that SFXN3 is involved in the transport and regulation of iron within the mitochondria, which is crucial for maintaining cellular health and function. Dysregulation of iron metabolism is associated with several pathological conditions, including neurodegenerative diseases and metabolic disorders. The recombinant expression of SFXN3 allows for detailed studies into its functional mechanisms and interactions with iron transporters and metabolic pathways. This has paved the way for investigating its potential as a therapeutic target. Understanding SFXN3’s role in iron handling and its broader implications in mitochondrial function may provide insights into novel therapeutic strategies aimed at mitigating diseases linked to iron dysregulation and mitochondrial dysfunction. The ongoing exploration of SFXN3 may contribute to the development of targeted interventions to restore iron balance and improve mitochondrial health in affected tissues.
